New drug ORB-021 enters early human testing for advanced cancers
Disease control
Recruiting now
This early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC